AstraZeneca's $15 billion pledge to its China operations highlights the country's advantages. But other regions are also hoping to host more clinical studies.

Innovations in clinical trial designs and tools have the potential to unlock a new era of research that is more convenient for patients, more reflective of real-world treatment conditions, and more ...

Xenon Pharmaceuticals provided an update on its pipeline programs, highlighting significant progress and upcoming milestones for 2025. The company anticipates topline data from its first Phase 3 study ...

New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support ...

Post-approval research on existing medicines has improved patient outcomes and addressed unmet medical needs. In oncology, post-approval improvements to drugs reflect indications for additional cancer ...

SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn.--(BUSINESS WIRE)--Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments in cancer, today ...

Clinical studies remain one of the most difficult phases in medical device development. They’re slow, expensive, and sometimes unpredictable — but completely necessary for nearly everything that ...

• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic ...

Representative clinical studies are important as diseases and medicines can affect people differently depending on their age, sex, and race and ethnicity. According to the Food and Drug Administration ...

Clinical Research An increasing number of companies are offshoring clinical research to Europe. But is that the best way to prepare a device for release in the United States? Nancy J. Stark and Jeff ...